INNOVIVA, INC. Increase (Decrease) in Accrued Interest Receivable, Net
INNOVIVA, INC. (INVA) reported Increase (Decrease) in Accrued Interest Receivable, Net of $1.10 million for the 9-month period ending 2013-09-30, per its 10-Q filed 2013-11-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet · last filed 2013-11-01
- INNOVIVA, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2013-09-30 was $3.64M.
- INNOVIVA, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2013-06-30 was -$2.71M.
- INNOVIVA, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2013-03-31 was $174.00K, a 86.55% decline year-over-year.
- INNOVIVA, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2012-03-31 was $1.29M.
| Period end | Increase (Decrease) in Accrued Interest Receivable, Net 3 month | Increase (Decrease) in Accrued Interest Receivable, Net 6 month | Increase (Decrease) in Accrued Interest Receivable, Net 9 month |
|---|---|---|---|
| 2013-09-30 | $3.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-01 | $925.00K derived: sum of 2 quarters · filed 2013-11-01 | $1.10M 10-Q · filed 2013-11-01 |
| 2013-06-30 | -$2.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | -$2.54M 10-Q · filed 2013-08-01 | |
| 2013-03-31 | $174.00K 10-Q · filed 2013-05-01 | ||
| 2012-03-31 | $1.29M 10-Q · filed 2013-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |